Last reviewed · How we verify
Neuromet (OXIRACETAM)
Neuromet (generic name: OXIRACETAM) is a oxiracetam drug. It is currently in Phase 3 development.
Neuromet works by enhancing the activity of neurotransmitters in the brain, such as acetylcholine, to improve cognitive function.
Neuromet, also known as OXIRACETAM, is a small molecule oxiracetam drug developed by UCB (originally developed by UCB, current owner is unknown). Its exact target is unknown, but it is believed to work by enhancing cholinergic neurotransmission and modulating glutamatergic activity. Neuromet is not FDA-approved for any indications, and its commercial status is unclear. Key safety considerations include its potential for hepatotoxicity and interactions with other medications. As a result, its use should be carefully monitored.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | OXIRACETAM |
|---|---|
| Drug class | oxiracetam |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 3 |
Mechanism of action
Think of it like a key that unlocks the doors to your brain's memory and learning centers. By enhancing the activity of these neurotransmitters, Neuromet helps improve communication between brain cells, leading to better memory, attention, and learning. This can be especially helpful for people with conditions that affect cognitive function, such as Alzheimer's disease or attention deficit hyperactivity disorder (ADHD).
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neuromet CI brief — competitive landscape report
- Neuromet updates RSS · CI watch RSS
Frequently asked questions about Neuromet
What is Neuromet?
How does Neuromet work?
What is the generic name of Neuromet?
What drug class is Neuromet in?
What development phase is Neuromet in?
Related
- Drug class: All oxiracetam drugs
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing